The consideration to sell Esbriet by Roche is a strategic move in response to declining sales due to generic competition. While this news indicates a proactive approach to portfolio management, the impact on the stock price in the short term is uncertain. The sale could be seen positively as a way to streamline operations and focus on more profitable areas, or negatively due to the loss of revenue from Esbriet. The high relevance score reflects the direct involvement of Roche in this decision, and the importance score is significant due to Esbriet's role in Roche's product lineup. The confidence level is set at 80, acknowledging the early stage of discussions and the unpredictability of market reactions.